[New antitubercular agents and their use in osteoarticular tuberculosis]. 1973

D Maar, and A Bajan, and C Havelka, and C Kopác

UI MeSH Term Description Entries
D002207 Capreomycin Cyclic peptide antibiotic similar to VIOMYCIN. It is produced by Streptomyces capreolus. Capreomycin Sulfate,Capastat,Capromycin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D014394 Tuberculosis, Osteoarticular Tuberculosis of the bones or joints. Bone Tuberculosis,Joint Tuberculosis,Bone Tuberculoses,Joint Tuberculoses,Osteoarticular Tuberculoses,Osteoarticular Tuberculosis,Tuberculoses, Bone,Tuberculoses, Joint,Tuberculoses, Osteoarticular,Tuberculosis, Bone,Tuberculosis, Joint

Related Publications

D Maar, and A Bajan, and C Havelka, and C Kopác
January 1974, Plucne bolesti i tuberkuloza,
D Maar, and A Bajan, and C Havelka, and C Kopác
February 1971, Polski tygodnik lekarski (Warsaw, Poland : 1960),
D Maar, and A Bajan, and C Havelka, and C Kopác
October 1968, Revista clinica espanola,
D Maar, and A Bajan, and C Havelka, and C Kopác
February 1961, Nordisk medicin,
D Maar, and A Bajan, and C Havelka, and C Kopác
July 2021, Medicinal research reviews,
D Maar, and A Bajan, and C Havelka, and C Kopác
April 1964, Magyar sebeszet,
D Maar, and A Bajan, and C Havelka, and C Kopác
March 2008, Revue medicale suisse,
D Maar, and A Bajan, and C Havelka, and C Kopác
March 1974, Ceskoslovenska pediatrie,
D Maar, and A Bajan, and C Havelka, and C Kopác
January 1962, Farmaceuticky obzor,
D Maar, and A Bajan, and C Havelka, and C Kopác
February 1954, Medicina y cirugia de guerra,
Copied contents to your clipboard!